Maxime Verhoeven

156 Chapter 7 Supplementary Figure 3 Cost effectiveness acceptability curve, for base case and per sensitivity analysis, for the TCZ+MTX initiation treatment strategy group versus the MTX initiation strategy group over 5 years, using the societal perspective (human capital approach). Base case= using data of all patients included in U-Act-Early; Complete case= using data of all patients also included in the post-trial follow-up; TCZ-SC= using TCZ subcutaneously; -10%= price reduction of 10%; -30%= price reduction of 30%. Supplementary Figure 4 Cost effectiveness acceptability curve, for base case and per sensitivity analysis, for the TCZ initiation treatment strategy group versus the MTX initiation strategy group over 5 years, using the societal perspective (human capital approach). Base case= using data of all patients included in U-Act-Early; Complete case= using data of all patients also included in the post-trial follow-up; TCZ-SC= using TCZ subcutaneously; -10%= price reduction of 10%; -30%= price reduction of 30%.